2. Immunology/Inflammation
  3. Toll-like Receptor (TLR) PD-1/PD-L1
  4. BXY-14

BXY-14 is a TLR2 agonist and vaccine adjuvant. BXY-14 significantly downregulates the expression of intratumoral PD-L1 in mouse models. BXY-14 acts as a vaccine adjuvant to induce antibody responses. BXY-14 exhibits synergistic efficacy when combined with the anti-PD-L1 monoclonal antibody Atezolizumab (HY-P9904) in mouse models of melanoma, and prolongs overall survival. BXY-14 is applicable to research related to melanoma.

For research use only. We do not sell to patients.

BXY-14

BXY-14 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

BXY-14 Related Antibodies

Top Publications Citing Use of Products

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms
TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BXY-14 is a TLR2 agonist and vaccine adjuvant. BXY-14 significantly downregulates the expression of intratumoral PD-L1 in mouse models. BXY-14 acts as a vaccine adjuvant to induce antibody responses. BXY-14 exhibits synergistic efficacy when combined with the anti-PD-L1 monoclonal antibody Atezolizumab (HY-P9904) in mouse models of melanoma, and prolongs overall survival. BXY-14 is applicable to research related to melanoma[1].

IC50 & Target[1]

TLR2

 

In Vitro

BXY-14 (1-106 pM) acts as a potent TLR2 agonist in hTHP-1 cells, inducing TNF-α release with an EC50 of 2.2 nM[1].
BXY-14 (10-3-103 nM; 24 h) is a potent TLR2 agonist in hPBMC that induces TNF-α release with an EC50 of 0.58 nM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BXY-14 Related Antibodies
In Vivo

BXY-14 (10-20 mg/kg; s.c.; on days 0, 14, and 28) functions as a potent vaccine adjuvant in mice, inducing stronger OVA-specific antibody responses with a Th1-skewed bias compared to Diprovocim, and is well-tolerated with no adverse body weight effects[1].
BXY-14 (10 mg/kg; s.c.; on days 0, 14, and 28) in combination with anti-PD-L1 enhances tumor growth inhibition, prolongs survival to 100% at day 50, and reduces intratumoral PD-L1 expression in a murine B16-OVA melanoma model, while BXY-14 (20 mg/kg; s.c.; on days 0, 14, and 28) as monotherapy also suppresses tumor growth and downregulates PD-L1[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (female, 6-8 weeks old, ~20 g)[1]
Dosage: 10 mg/kg; 20 mg/kg
Administration: s.c.; on days 0, 14, and 28
Result: Induced significantly stronger total IgG, IgG1, and IgG2c anti-OVA antibody titers than positive control adjuvant Diprovocim on day 42, with a marked Th1-skewed immune bias (higher Th1/Th2 index) at 10 mg/kg.
Induced robust total IgG, IgG1, and IgG2c anti-OVA antibody titers, with no significant body weight changes observed over 10 days post-immunization, indicating good tolerance at 20 mg/kg.
Animal Model: C57BL/6 (female, 6-8 weeks old, ~20 g, subcutaneously injected with 2×105 B16-OVA melanoma cells on day 42 post-initial immunization)[1]
Dosage: 10 mg/kg (in combination with anti-PD-L1); 20 mg/kg (monotherapy)
Administration: s.c.; on days 0, 14, and 28
Result: Achieved stronger tumor growth inhibition than Diprovocim plus anti-PD-L1, prolonged overall survival to 100% at day 50, significantly increased tumor cell apoptosis (higher mean fluorescence intensity of TUNEL staining), and markedly downregulated intratumoral PD-L1 expression (lower integrated optical density of PD-L1 staining) at 10 mg/kg in combination with anti-PD-L1.
Potently suppressed tumor growth, prolonged survival, and downregulated intratumoral PD-L1 expression at 20 mg/kg as monotherapy.
Molecular Weight

646.89

Formula

C35H66O10
SMILES

O[C@@H]1[C@H]([C@@H](O[C@H]1OC[C@@H](COC(CCCCCCCCCCCC)=O)O)[C@H](O)COC(CCCCCCCCCCCC)=O)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BXY-14 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BXY-14BXY14BXY 14Toll-like Receptor (TLR)PD-1/PD-L1PD-1/Programmed death-ligand 1human THP-1 cellsPD-L1TLR2murine TLR2melanomamurine bone marrow-derived dendritic cellshuman TLR2human monocytic cellsmurine modelsanti-PD-L1 monoclonal antibody atezolizumabInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BXY-14
Cat. No.:
HY-181916
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.